Journey Medical (DERM) Liabilities and Shareholders Equity (2020 - 2026)

Journey Medical (DERM) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $98.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 21.19% year-over-year to $98.4 million; the trailing twelve-month figure through Jun 2026 stood at $369.7 million (up 19.09% YoY), and the FY2025 full-year result was $94.6 million, up 17.88% from the prior year.
• Liabilities and Shareholders Equity improved to $98.4 million in Q2 2026 per DERM's latest filing, from $91.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $120.9 million in Q1 2022 and bottomed at $64.0 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $87.1 million across 5 years, with a median of $85.1 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity slumped 39.05% in 2023, then soared 33.02% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $105.2 million in 2022, then declined by 26.92% to $76.8 million in 2023, then gained by 4.41% to $80.2 million in 2024, then grew by 17.88% to $94.6 million in 2025, then rose by 3.98% to $98.4 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $98.4 million, $91.5 million, and $94.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.